Phenotypes associated with this allele
|
Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm4(CAG-hsb5)Nki mutation
(0 available);
any
Gt(ROSA)26Sor mutation
(944 available)
Npm1tm1Gsva mutation
(0 available);
any
Npm1 mutation
(33 available)
Tg(Mx1-cre)1Cgn mutation
(7 available)
TgTn(pb-sb-GrOnc)#aGsva mutation
(0 available)
|
|
|
mortality/aging
|
• mean survival of pIpC-treated mice is 99 days compared with 150 days for Gt(Rosa)26Sortm4(CAG-hsb5)Nki Gt(Rosa)26Sor+ Tg(Mx1-cre)1Cgn TgTn(pb-sb-GrOnc)#aGsva control mice
|
neoplasm
|
• all mice develop aggressive leukemia and/or lymphoma within a year of pIpC induction
|
|
• all mice develop aggressive leukemia and/or lymphoma within a year of pIpC induction
• however, pIpC-treated mice do not develop T cell lymphomas unlike in control mice
|
|
• in some pIpC-treated mice
|
|
• angiosarcoma in some pIpC-treated mice
|
|
Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm4(CAG-hsb5)Nki mutation
(0 available);
any
Gt(ROSA)26Sor mutation
(944 available)
Tg(Mx1-cre)1Cgn mutation
(7 available)
Tg(Tal1-tTA)19Dgt mutation
(2 available)
Tg(tetO-BCR/ABL1)2Dgt mutation
(1 available)
TgTn(pb-sb-GrOnc)#aGsva mutation
(0 available)
|
|
|
mortality/aging
|
• mice withdrawn from tetracycline and treated with polyinosine-polycyticylic acid (pIpC) show a decrease in survival with median survival of 116.5 days
|
neoplasm
|
• majority of pIpC treated mice (85%) develop an exclusively myeloid and primary acute leukemia phenotype
• 5% of mice remain in the chronic phase of the disease
• about 10% of mice develop an accelerated phase-like phenotype but with less than 20% blasts
• however, mice do not develop lymphoid leukemias
|
hematopoietic system
|
• hemoglobin levels are decreased in pIpC treated mice
|
|
• upon withdrawal of tetracycline and treatment with pIpC, mice develop moderate, but persistent (2-3 fold) increase of white blood counts
• white blood cell counts at the terminal endpoint are elevated, indicating a dramatic preterminal proliferative change in kinetics of their disease
|
|
• upon withdrawal of tetracycline and treatment with pIpC, mice show marked expansion of the granulocyte compartment
• increase in infiltration of tissues with both granulocytes and immature cells
|
|
• disease progression in in pIpC treated mice is frequently accompanied by an increase in basophils
|
|
• the myeloid progenitor compartment is expanded in pIpC treated mice, including the granulocyte monocyte progenitor compartment
|
|
• expansion of the lineage-negative (Lin-) bone marrow fraction in pIpC treated mice
• however, no differences are seen in total Lin-Sca+c-kit+ (LSK) numbers, long-term and short-term hematopoietic stem cell or multipotent progenitor proportions
|
|
• hematopoietic stem cells show an increased ability to serially replate compared to control cells
|
immune system
|
• upon withdrawal of tetracycline and treatment with pIpC, mice develop moderate, but persistent (2-3 fold) increase of white blood counts
• white blood cell counts at the terminal endpoint are elevated, indicating a dramatic preterminal proliferative change in kinetics of their disease
|
|
• upon withdrawal of tetracycline and treatment with pIpC, mice show marked expansion of the granulocyte compartment
• increase in infiltration of tissues with both granulocytes and immature cells
|
|
• disease progression in in pIpC treated mice is frequently accompanied by an increase in basophils
|
liver/biliary system
growth/size/body
|
Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm4(CAG-hsb5)Nki mutation
(0 available);
any
Gt(ROSA)26Sor mutation
(944 available)
Tg(Mx1-cre)1Cgn mutation
(7 available)
Tg(tetO-BCR/ABL1)2Dgt mutation
(1 available)
TgTn(pb-sb-GrOnc)#aGsva mutation
(0 available)
|
|
|
mortality/aging
|
• mice withdrawn from tetracycline and treated with polyinosine-polycyticylic acid (pIpC) show a median survival of 125.5 days
|
neoplasm
|
• 26% of mice treated with pIpC develop lymphoid acute leukemias
• 70% of mice treated with pIpC develop myeloid acute leukemias
• increase in infiltration of tissues with immature cells
|